Aetna International is set to take over Aviva UK’s IPMI division

By Catherine Sturman
Leading global health care benefits provider, Aetna International has entered an agreement to acquire Aviva UK’s International Private Medical Insuran...

Leading global health care benefits provider, Aetna International has entered an agreement to acquire Aviva UK’s International Private Medical Insurance (IPMI) operations. From May 2018, Aviva UK will no longer provide IPMI cover for new customers or for existing customers wishing to renew their policies. 

Serving over 700,000 million members worldwide, Aetna International offers a multitude of services, delivering comprehensive health care benefits, alongside customised technological and health management solutions, covering health care systems, government entities and large employers.

Under the agreement, existing Aviva IPMI customers will be offered continuation terms at policy renewal with Aetna International. Existing Aviva customers who renew their policy will then become Aetna customers and will no longer have a relationship with Aviva.

See also

David Healy, CEO EMEA at Aetna International said: “We are delighted to have reached this agreement with Aviva. 

We are committed to delivering Aviva’s IPMI customers continuation of cover with Aetna that provides comparable benefits and an excellent level of service. This is very much in line with our business strategy to deliver comprehensive health care benefits worldwide.

Our scale, expertise, customer service infrastructure and technological focus in IPMI allow us to make a significant contribution to improving people’s health and the quality of care they receive.”

Share

Featured Articles

Comarch Diagnostic Point Boost for European Health Insurance

Healthtech specialist Comarch introduces Diagnostic Point, designed to improve health insurance across European markets

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Procurement & Supply Chain

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma